Intervention not reported
Any serious adverse events ( · people with relapsed or refractory DLBCL
1 finding from 1 review
- Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma 2021 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 281 participantsVery low